San Diego, CA, January 9, 2025 – Inmagene Biopharmaceuticals (“Inmagene” or the “Company”), a clinical-stage biotechnology company developing innovative and […]
BOSTON, MA and SAN DIEGO, CA, December 23, 2024, – Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,”) and Inmagene Biopharmaceuticals (“Inmagene”)
San Diego, CA, October 9, 2024 – Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotechnology company developing innovative and differentiated therapies for
San Diego, CA, June 27, 2024 – Inmagene Biopharmaceuticals (“Inmagene” or the “Company”), a clinical-stage biotechnology company developing innovative and
San Diego, CA, May 7, 2024 – Inmagene Biopharmaceuticals (“Inmagene” or the “Company”), a clinical-stage biotechnology company developing innovative and
Treatment with IMG-007, the only clinical-stage nondepleting anti-OX40 monoclonal antibody (mAb), led to rapid, marked, and durable improvement of skin
Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40
IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12 weeks dosing and an improved safety
San Diego, California, September 21, 2023 – Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotech company developing innovative and differentiated therapies for immunological
IMG-007 has the potential to provide Q12W or less frequent dosing based on an extended half-life IMG-007 has demonstrated a
